Fullerene-biomolecule conjugates and their biomedicinal applications

International Journal of Nanomedicine

Volumn 9, Issue 1, 2013, Pages 77-92

  Yang, Xinlin ^a   Ebrahimi, Ali ^a   Li, Jie ^a,b   Cui, Quanjun ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Amino acid; Ester; Fullerene; Oligonucleotide; Peptide; Sugar

Indexed keywords

ACETYLCHOLINESTERASE; FULLERENE DERIVATIVE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE;

ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; BIOMEDICINE; BONE DEVELOPMENT; CELL DEATH; CELL INTERACTION; CELL MEMBRANE; CELL PROTECTION; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME METABOLISM; ERYTHROCYTE AGGREGATION; ESCHERICHIA COLI; HUMAN; LIPOPHILICITY; MEMBRANE DEPOLARIZATION; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MYCOBACTERIUM TUBERCULOSIS; NEUROPROTECTION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN SYNTHESIS; PYRAMIDAL NERVE CELL; REVIEW; STAPHYLOCOCCUS AUREUS;

AMINO ACID; ESTER; FULLERENE; OLIGONUCLEOTIDE; PEPTIDE; SUGAR;

ANTIOXIDANTS; BIOPOLYMERS; DRUG COMPOUNDING; FULLERENES; NANOCAPSULES; PARTICLE SIZE;

EID: 84890862428     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S52829     Document Type: Review

References (87)

1. Kroto H W, Heath JR, O'Brien SC, Curl RF, Smalley RE. C60: Buckminsterfullerene. Nature. 1985;318:162-163.
2. Friedman SH, DeCamp DL, Sijbesma R P, Srdanov G, Wudl F, Kenyon GL. Inhibition of the HIV-1 protease by fullerene derivatives: model building studies and experimental verification. J Am Chem Soc. 1993;115(15):6506-6509.
3. Schinazi RF, Sijbesma R, Srdanov G, Hill CL, Wudl F. Synthesis and virucidal activity of a water-soluble, confgurationally stable, derivatized C60 fullerene. Antimicrob Agents Chemother. 1993;37(8): 1707-1710.
4. Pantarotto D, Tagmatarchis N, Bianco A, Prato M. Synthesis and biological properties of fullerene-containing amino acids and peptides. Mini Rev Med Chem. 2004;4(7):805-814.
5. Foley S, Crowley C, Smaihi M, et al. Cellular localisation of a water-soluble fullerene derivative. Biochem Bioph Res Commun. 2002;294(1): 116-119.
6. Rajagopalan P, Wudl F, Schinazi RF, Boudinot FD. Pharmacokinetics of a water-soluble fullerene in rats. Antimicrob Agents Chemother. 1996;40(10):2262-2265.
7. Bosi S, Da Ros T, Spalluto G, Prato M. Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem. 2003;38(11-12): 913-923.
8. Paradise WA, Vesper BJ, Goel A, et al. Nitric oxide: perspectives and emerging studies of a well known cytotoxin. Int J Mol Sci. 2010;11(7): 2715-2745.
9. Hur J, Pak SC, Koo BS, Jeon S. Borneol alleviates oxidative stress via upregulation of Nrf2 and Bcl-2 in SH-SY5Y cells. Pharm Biol. 2013;51(1):30-35.
10. Higashi N, Shosu T, Koga T, Niwa M, Tanigawa T. Ph-responsive, self-assembling nanoparticle from a fullerene-tagged poly(L-glutamic acid) and its superoxide dismutase mimetic property. J Colloid Interface Sci. 2006;298(1):118-123.
11. Yang J, Alemany LB, Driver J, Hartgerink JD, Barron AR. Fullerene-derivatized amino acids: synthesis, characterization, antioxidant properties, and solid-phase peptide synthesis. Chemistry. 2007;13(9): 2530-2545.
12. Ioannou E, Hirsch A, Elemes Y. Sulfur-containing dihydro-pyrrolo [60] fullerene derivatives via 1,3-dipolar cycloadditions of glycine imine esters to C60. Tetrahedron. 2007;63(30):7070-7076.
13. Hu Z, Guan W, Wang W, Huang L, Xing H, Zhu Z. Synthesis of beta-alanine C60 derivative and its protective effect on hydrogen peroxide-induced apoptosis in rat pheochromocytoma cells. Cell Biol Int. 2007;31(8):798-804.
14. Hu Z, Guan W, Wang W, Huang L, Xing H, Zhu Z. Protective effect of a novel cystine C(60) derivative on hydrogen peroxide-induced apoptosis in rat pheochromocytoma PC12 cells. Chem Biol Interact. 2007;167(2):135-144.
15. Chen T, Li Y Y, Zhang JL, et al. Protective effect of C(60)-methionine derivate on lead-exposed human SH-SY5Y neuroblastoma cells. J Appl Toxicol. 2011;31(3):255-261.
16. Cusan C, Da Ros T, Spalluto G, et al. A new multi-charged C60 derivative: synthesis and biological properties. European J Org Chem. 2002;(17):2928-2934.
17. Kraszewski S, Tarek M, Ramseyer C. Uptake and translocation mechanisms of cationic amino derivatives functionalized on pristine C60 by lipid membranes: a molecular dynamics simulation study. ACS Nano. 2011;5(11):8571-8578.
18. Basso AS, Frenkel D, Quintana FJ, et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest. 2008;118(4):1532-1543.
19. Makarova EG, Gordon RY, Podolski I Y. Fullerene C60 prevents neuro-toxicity induced by intrahippocampal microinjection of amyloid-beta peptide. J Nanosci Nanotechnol. 2012;12(1):119-126.
20. Fujimoto T, Ito S, Ito M, Kanazawa H, Yamaguchi S. Induction of different reactive oxygen species in the skin during various laser therapies and their inhibition by fullerene. Laser Surg Med. 2012;44(8):685-694.
21. Liu HJ, Yang XL, Zhang Y, Dighe A, Li XD, Cui QJ. Fullerol antagonizes dexamethasone-induced oxidative stress and adipogenesis while enhancing osteogenesis in a cloned bone marrow mesenchymal stem cell. J Orthop Res. 2012;30(7):1051-1057.
22. Cai X, Jia H, Liu Z, et al. Polyhydroxylated fullerene derivative C(60) (OH)(24) prevents mitochondrial dysfunction and oxidative damage in an MPP(+)-induced cellular model of Parkinson's disease. J Neurosci Res. 2008;86(16):3622-3634.
23. Mashino T, Shimotohno K, Ikegami N, et al. Human immunodefciency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives. Bioorg Med Chem Lett. 2005;15(4):1107-1109.
24. Meng X, Li B, Chen Z, et al. Inhibition of a thermophilic deoxyribo-nucleic acid polymerase by fullerene derivatives. J Enzyme Inhib Med Chem. 2007;22(3):293-296.
25. Yang X, Meng X, Li B, et al. Inhibition of in vitro amplifcation of targeted DNA fragment and activity of exonuclease I by a fullerene-oligonucleotide conjugate. Biologicals. 2008;36(4):223-226.
26. Shang J, Ratnikova TA, Anttalainen S, Salonen E, Ke PC, Knap HT. Experimental and simulation studies of a real-time polymerase chain reaction in the presence of a fullerene derivative. Nanotechnology. 2009;20(41):415101.
27. Nedumpully Govindan P, Monticelli L, Salonen E. Mechanism of taq DNA polymerase inhibition by fullerene derivatives: insight from computer simulations. J Phys Chem B. 2012;116(35):10676-10683.
28. Maoyong S, Guibin J, Junfa Y, Hailin W. Inhibition of polymerase activity by pristine fullerene nanoparticles can be mitigated by abundant proteins. Chem Commun (Camb). 2010;46(9):1404-1406.
29. Toniolo C, Bianco A, Maggini M, et al. A bioactive fullerene peptide. J Med Chem. 1994;37(26):4558-4562.
30. Pastorin G, Marchesan S, Hoebeke J, et al. Design and activity of cationic fullerene derivatives as inhibitors of acetylcholinesterase. Org Biomol Chem. 2006;4(13):2556-2562.
31. Patel MB, Harikrishnan U, Valand NN, Modi NR, Menon SK. Novel cationic quinazolin-4(3H)-one conjugated fullerene nanoparticles as antimycobacterial and antimicrobial agents. Arch Pharm (Weinheim). 2013;346(3):210-220.
32. Bosi S, Da Ros T, Spalluto G, Balzarini J, Prato M. Synthesis and anti-HIV properties of new water-soluble bis-functionalized[60]fullerene derivatives. Bioorg Med Chem Lett. 2003;13(24):4437-4440.
33. Pantarotto D, Bianco A, Pellarini F, et al. Solid-phase synthesis of fullerene-peptides. J Am Chem Soc. 2002;124(42):12543-12549.
34. Pellarini F, Pantarotto D, Da Ros T, Giangaspero A, Tossi D, Prato N. A novel [60]fullerene amino acid for use in solid-phase peptide synthesis. Org Lett. 2001;3(12):1845-1848.
35. Mashino T, Usui N, Okuda K, Hirota T, Mochizuki M. Respiratory chain inhibition by fullerene derivatives: hydrogen peroxide production caused by fullerene derivatives and a respiratory chain system. Bioorg Med Chem. 2003;11(7):1433-1438.
36. Tsao N, Luh T Y, Chou CK, et al. In vitro action of carboxyfullerene. J Antimicrob Chemother. 2002;49(4):641-649.
37. Tsao N, Kanakamma P P, Luh TY, Chou CK, Lei HY. Inhibition of Escherichia coli-induced meningitis by carboxyfullerence. Antimicrob Agents Chemother. 1999;43(9):2273-2277.
38. Tsao N, Wu CM, Hsu H P, et al. Inhibition of the increased permeability of blood-brain barrier in Escherichia coli-induced meningitis by carboxy-fullerene. Fullerene Science and Technology. 2001;9(3): 307-320.
39. Patel MB, Kumar S P, Valand NN, Jasrai YT, Menon SK. Synthesis and biological evaluation of cationic fullerene quinazolinone conjugates and their binding mode with modeled Mycobacterium tuberculosis hypoxanthine-guanine phosphoribosyltransferase enzyme. J Mol Model. 2013;19(8):3201-3217.
40. Huang LY, Terakawa M, Zhiyentayev T, et al. Innovative cationic fuller-enes as broad-spectrum light-activated antimicrobials. Nanomedicine. 2010;6(3):442-452.
41. Mizuno K, Zhiyentayev T, Huang L, et al. Antimicrobial photodynamic therapy with functionalized fullerenes: quantitative structure-activity relationships. J Nanomed Nanotechnol. 2011;2(2):1-9.
42. Chen BX, Wilson SR, Das M, Coughlin DJ, Erlanger BF. Antigenicity of fullerenes: Antibodies specifc for fullerenes and their characteristics. Proc Natl Acad Sci U S A. 1998;95(18):10809-10813.
43. Tkach AV, Yanamala N, Stanley S, et al. Graphene oxide, but not fuller-enes, targets immunoproteasomes and suppresses antigen presentation by dendritic cells. Small. 2013;9(9-10):1686-1690.
44. Ramsdale TE, Andrews PR, Nice EC. Verifcation of the interaction between peptide T and CD4 using surface-plasmon resonance. FEBS Lett. 1993;333(3):217-222.
45. Marastoni M, Salvadori S, Balboni G, et al. Structure-activity-relationships of peptide T-related pentapeptides. Arzneimittelforschung. 1989;39(8):926-928.
46. Sofou P, Elemes Y, Panou-Pomonis E, et al. Synthesis of a proline-rich [60]fullerene peptide with potential biological activity. Tetrahedron. 2004;60(12):2823-2828.
47. Petrovas CJ, Vlachoyiannopoulos PG, Tzioufas AG, et al. A major Sm epitope anchored to sequential oligopeptide carriers is a suitable antigenic substrate to detect anti-Sm antibodies. J Immunol Methods. 1998;220(1-2):59-68.
48. Sakarellos C, Tsikaris V, Panou-Pomonis E, et al. The PPGMRPP repetitive epitope of the Sm autoantigen: antigenic specifcity induced by conformational changes. Application of the Sequential Oligopeptide Carriers (SOCs). Letters in Peptide Science. 1997;4(4-6):447-454.
49. Bianco A, Pantarotto D, Hoebeke J, Briand J P, Prato M. Solid-phase synthesis and characterization of a novel fullerene-peptide derived from histone H3. Org Biomol Chem. 2003;1(23):4141-4143.
50. Bunz H, Plankenhorn S, Klein R. Effect of buckminsterfullerenes on cells of the innate and adaptive immune system: an in vitro study with human peripheral blood mononuclear cells. Int J Nanomedicine. 2012;7:4571-4580.
51. Andreev IM, Romanova VS, Petrukhina AO, Andreev SM. Amino-acid derivatives of fullerene C60 behave as lipophilic ions penetrating through biomembranes. Physics of the Solid State. 2002;44(4):683-685.
52. Kotelnikova RA, Kotelnikov AI, Bogdanov GN, et al. Membranotropic properties of the water soluble amino acid and peptide derivatives of fullerene C-60. FEBS Lett. 1996;389(2):111-114.
53. Kotelnikova RA, Bogdanov GN, Frog EC, et al. Nanobionics of pharmacologically active derivatives of fullerene C60. J Nanopart Res. 2003;5(5-6):561-566.
54. Rouse JG, Yang JZ, Ryman-Rasmussen J P, Barron AR, Monteiro-Riviere NA. Effects of mechanical fexion on the penetration of fullerene amino acid-derivatized peptide nanoparticles through skin. Nano Lett. 2007;7(1):155-160.
55. Isobe H, Nakanishi W, Tomita N, Jinno S, Okayama H, Nakamura E. Nonviral gene delivery by tetraamino fullerene. Mol Pharm. 2006;3(2): 124-134.
56. Isobe H, Nakanishi W, Tomita N, Jinno S, Okayama H, Nakamura E. Gene delivery by aminofullerenes: structural requirements for effcient transfection. Chem Asian J. 2006;1(1-2):167-175.
57. Maeda-Mamiya R, Noiri E, Isobe H, et al. In vivo gene delivery by cationic tetraamino fullerene. Proc Natl Acad Sci U S A. 2010;107(12): 5339-5344.
58. Yang J, Wang K, Driver J, Barron AR. The use of fullerene substituted phenylalanine amino acid as a passport for peptides through cell membranes. Org Biomol Chem. 2007;5(2):260-266.
59. Partha R, Conyers JL. Biomedical applications of functionalized fullerene-based nanomaterials. Int J Nanomedicine. 2009;4:261-275.
60. Amirshahi N, Alyautdin RN, Sarkar S, et al. Fullerene-based low toxic nanocationite particles (porphyrin adducts of cyclohexyl fullerene-C(60)) to treat hypoxia-induced mitochondrial dysfunction in mammalian heart muscle. Arch Med Res. 2008;39(6):549-559.
61. Shetab Boushehri S V, Ostad SN, Sarkar S, et al. The C60-fullerene por-phyrin adducts for prevention of the doxorubicin-induced acute cardio-toxicity in rat myocardial cells. Acta Med Iran. 2010;48(5):342-350.
62. Bernstein R, Prat F, Foote CS. On the mechanism of DNA cleavage by fullerenes investigated in model systems: Electron transfer from guanosine and 8-oxo-guanosine derivatives to C-60. J Am Chem Soc. 1999;121(2):464-465.
63. Prat F, Hou CC, Foote CS. Determination of the quenching rate constants of singlet oxygen by derivatized nucleosides in nonaqueous solution. J Am Chem Soc. 1997;119(21):5051-5052.
64. Da Ros T, Spalluto G, Boutorine AS, Bensasson RV, Prato M. DNA-photocleavage agents. Curr Pharm Des. 2001;7(17):1781-1821.
65. Bergamin M, Da Ros T, Spalluto G, Boutorine A, Prato M. Synthesis of a hybrid fullerene-trimethoxyindole-oligonucleotide conjugate. Chem Commun (Camb). 2001;1:17-18.
66. Da Ros T, Bergamin M, Vazquez E, et al. Synthesis and molecular modeling studies of fullerene-5,6,7-trimethoxyindole-oligonucleotide conjugates as possible probes for study of photochemical reactions in DNA triple helices. European J Org Chem. 2002;(3):405-413.
67. Klumpp C, Lacerda L, Chaloin O, et al. Multifunctionalised cationic fullerene adducts for gene transfer: design, synthesis and DNA complexation. Chem Commun (Camb). 2007;(36):3762-3764.
68. Montellano A, Da Ros T, Bianco A, Prato M. Fullerene C60 as a multi functional system for drug and gene delivery. Nanoscale. 2011;3(10) 4035-4041.
69. Hamazawa A, Kinoshita I, Breedlove B, et al. Meso-tetraphenylporphy rin having hexa-maltosyl and decyl chain as an amphiphilic photosen sitizer toward photodynamic therapy. Chem Lett. 2002;(3):388-389.
70. Mikata Y, Onchi Y, Shibata M, et al. Synthesis and phototoxic property of tetra- and octa-glycoconjugated tetraphenylchlorins. Bioorg Med Chem Lett. 1998;8(24):3543-3548.
71. Mikata Y, Onchi Y, Tabata K, et al. Sugar-dependent photocytotoxic property of tetra- and octa-glycoconjugated tetraphenylporphyrins Tetrahedron Lett. 1998;39(25):4505-4508.
72. Zheng G, Graham A, Shibata M, et al. Synthesis of beta-galactose conjugated chlorins derived by enyne metathesis as galectin-specifc photosensitizers for photodynamic therapy. J Org Chem. 2001;66(26) 8709-8716.
73. Mikata Y, Takagi S, Tanahashi M, et al. Detection of 1270 nm emission from singlet oxygen and photocytotoxic property of sugar-pendant 60 fullerenes. Bioorg Med Chem Lett. 2003;13(19):3289-3292.
74. Enes RF, Tomé AC, Cavaleiro JAS, El-Agamey A, McGarvey DJ Synthesis and solvent dependence of the photophysical proper ties of [60]fullerene-sugar conjugates. Tetrahedron. 2005;61(50) 11873-11881.
75. Filippone S, Heimann F, Rassat A. A highly water-soluble 2:1 beta-cyclodextrin-fullerene conjugate. Chem Commun (Camb) 2002;(14):1508-1509.
76. Liu Y, Liang P, Chen Y, Zhao YL, Ding F, Yu A. Spectrophotometric study of fuorescence sensing and selective binding of biochemica substrates by 2,2′-bridged biso(beta-cyclodextrin) and its water-soluble fullerene conjugate. J Phys Chem B. 2005;109(49):23739-23744.
77. Xiao SL, Wang Q, Yu F, et al. Conjugation of cyclodextrin with fullerene as a new class of HCV entry inhibitors. Bioorg Med Chem 2012;20(18):5616-5622.
78. Kato H, Yashiro A, Mizuno A, Nishida Y, Kobayashi K, Shinohara H Syntheses and biological evaluations of alpha-D-mannosyl [60 fullerenols. Bioorg Med Chem Lett. 2001;11(22):2935-2939.
79. Tanimoto S, Sakai S, Kudo E, et al. Target-selective photodegra dation of HIV-1 protease and inhibition of HIV-1 replication in living cells by designed fullerene-sugar hybrids. Chem Asian J 2012;7(5):911-914.
80. Schergna S, Da Ros T, Linda P, Ebert C, Gardossi L, Prato M. Enzymatic modifcation of fullerene derivatives. Tetrahedron Lett. 1998;39(42) 7791-7794.
81. Peng QY, Kang F, Li JA, Yang XL. Degradation of a fullerene end capped polycaprolactone by lipase AK. Chin Sci Bull. 2010;55(29) 3279-3282.
82. Enes RF, Farinha ASF, Tomé AC, et al. Synthesis and antioxi dant activity of [60]fullerene-flavonoid conjugates. Tetrahedron 2009;65(1):253-262.
83. Liu RL, Yin JJ, Li WX. Synthesis of glucocorticoid-C60 hybrids. Carbon 2006;44(2):387-388.
84. Liu R, Cai X, Wang J, Li J, Huang Q, Li W. Research on the bioac tivities of C60-dexamethasone. J Nanosci Nanotechnol. 2009;9(5) 3171-3176.
85. Zhang Y, Wang L, Sun Y, et al. Conjugation of dexamethasone to C60 for the design of an anti-infammatory nanomedicine with reduced cellular apoptosis. ACS Appl Mater Interfaces. 2013;5(11) 5291-5297.
86. Powell C, Chang C, Gershwin ME. Current concepts on the pathogenesi and natural history of steroid-induced osteonecrosis. Clin Rev Allergy Immunol. 2011;41(1):102-113.
87. Manolagas SC. From estrogen-centric to aging and oxidative stress a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010;31(3):266-300.